Drugs do not metabolize the same way in all people. For what patient would a nurse expect to assess for an alteration in drug metabolism?

A) Norepinephrine: Norepinephrine is a potent vasoconstrictor primarily used in cases of shock to increase blood pressure by constricting blood vessels. However, it does not have a vasodilatory effect on renal blood vessels. Instead, it tends to decrease renal perfusion due to its strong vasoconstrictor properties, which could worsen renal insufficiency.

B) Dopamine: Dopamine is a catecholamine that has a dose-dependent effect on various receptors. At low doses, dopamine specifically acts on dopaminergic receptors in the kidneys, leading to vasodilation of renal blood vessels, which can improve renal perfusion. This makes it particularly useful in treating shock when there is concern about renal insufficiency or reduced kidney function.

C) Acetylcholine: Acetylcholine is a neurotransmitter of the parasympathetic nervous system, not a catecholamine. It is involved in promoting various physiological effects such as slowing the heart rate and stimulating digestive processes, but it does not have a specific role in vasodilation of renal blood vessels or shock management.

D) Enkephalin: Enkephalins are endogenous peptides involved in the regulation of pain and stress responses. They do not have a direct effect on vasodilation of renal blood vessels. Enkephalins are not typically used to treat shock or manage renal insufficiency.

A) “Alzheimer disease affects memory but not personality.”
While memory loss is one of the hallmark symptoms of Alzheimer’s disease, the condition also significantly impacts other cognitive functions, including personality and behavior. As the disease progresses, patients often experience changes in mood, behavior, and personality, such as increased irritability, depression, or aggression.

B) “With proper treatment, symptoms of this disease can be arrested.”
Currently, there is no cure for Alzheimer’s disease, and while some treatments (like cholinesterase inhibitors) can help manage symptoms temporarily or slow their progression, the disease itself is not arrestable. The goal of treatment is to manage symptoms and improve quality of life, but it cannot stop the disease from advancing.

C) “The onset of Alzheimer disease is usually between 65 and 75 years.”
While Alzheimer’s disease typically affects older adults, this statement is too narrow. Alzheimer’s disease can begin earlier, sometimes in individuals in their 50s or 60s, particularly in cases of early-onset Alzheimer’s. The average age of onset for most people is around 65, but there is variability.

D) “Alzheimer disease is a chronic, progressive condition.”
Alzheimer’s disease is indeed chronic (lasting for years) and progressive (it worsens over time). It gradually destroys brain cells, leading to a decline in cognitive function, including memory, thinking, and reasoning skills. This is the fundamental nature of the disease